Dry Eye Syndrome Market Size, Share, Growth, Opportunities and Global Forecast to 2028

Global Dry Eye Syndrome Treatment Market: Overview

Dry eye syndrome (DES) is also known as keratisis sicca and kerato-conjunctivitis sicca. People suffering from DES show damage to the ocular surface, instability in the tear film, and visual disturbance. Tear film covers the ocular surface, which is made up of three intertwined layers, a superficial lipid layer, produced by meibomian glands assist in reducing tear evaporation and uniform tear spreading, middle thick aqueous layer produced from lacrimal glands, and the innermost hydrophilic mucin layer produced from goblet cells of conjunctiva and epithelium of ocular surface.

Report For Sample with Table of Contents@ https://www.researchreportinsights.com/report/sample/110114612/Dry-Eye-Syndrome-Treatment-Market

The two most common types of DES are DES associated with Sjogren syndrome (SS) and DES unassociated with SS. DES can also be classified as aqueous deficiency dry eye and evaporative dry eye disorder. According to TearScience Inc., in 2012, around 86% of the patients in Europe and the U.S. were suffering from DES showed symptoms of Meibomian Gland Dysfunction (MGD, blockage of meibomian glands). The blockage causes less secretion of oil in the tears, which results in evaporation of tears too quickly.

The global dry eye syndrome treatment market is primarily driven by growing geriatric population coupled with high prevalence of dry eye syndrome and growth in awareness about the diagnosis and treatment of the disease. However, the stringent drug approvals, expirations of the blockbuster drugs patents, and lack of skilled ophthalmologists are restraining the growth of DES market. According to National Health and Wellness Survey in 2013, approximately 16.4 million people are suffering from DES, which accounts for 6.8% of the total population of the U.S. Prevalence of DES increases with age, 2.7% for 18 - 34 age group and 18.6% for more than 75 age group were reported to be suffering from DES. The prevalence of DES is higher in women (8.8%) as compared to men (4.5%). According to the National Eye Institute, in the U.S the annual cost of treating DES including prescription drugs is US $3.84 billion.

Global Dry Eye Syndrome Treatment Market: Segmentation

By Product Type

• Cyclosporine
• Oral Corticosteroid
• Artificial Tears
• Omega Supplements
• Punctual Bags

• Removable Bags
• Dissolvable Bags

By Disease Type:

• Evaporative Dry Eye Syndrome
• Aqueous Dry Eye Syndrome

By Product

• Liquid Drops
• Gel
• Liquid Wipes
• Eye Ointment

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

  Request For Report Discount@ https://www.researchreportinsights.com/report/discount/110114612/Dry-Eye-Syndrome-Treatment-Market

High healthcare expenditure and increasing R&D activities in the DES treatment market is expected to propel growth of DES market in North America

Growing geriatric population coupled with high prevalence of dry eye syndrome owing to lifestyle disorders are contributing factors for the growth of DES market in the North America region.

Asia Pacific region is emerging in DES treatment market due to large pool of patient population. According to the regional population based study published in All India Ophthalmological Society, in 2012, the prevalence of DES was 40.8% with mild symptoms and 31.7% with MGD.

Global dry eye syndrome treatment market is oligopolistic in nature with few players holding majority of the share. Various strategies are adopted by market players such as new product launches, acquisitions, and agreements in order to retain market position. In September, 2017, Johnson and Johnson Vision, acquired TearScience Inc., a medical device manufacturer for treating MGD. This acquisition expanded the company’s eye health portfolio. In April 2017, Allergan received marketing approval from FDA for its TrueTear Intranasal Tear Neurostimulator.

Some of the major players operating in the global dry eye syndrome treatment market are Allergan, Novartis AG., Otsuka Pharmaceutical Co. Ltd., Valent Pharmaceuticals, Johnson and Johnson Vision, Acadia Pharmaceuticals, Allostera Pharma, I-Med Pharma Inc., Santen Pharmaceuticals Co. Ltd., AFT pharmaceuticals, Novaliq GmBh, and Auven therapeutics.

Report Analysis@ https://www.researchreportinsights.com/report/rd/110114612/Dry-Eye-Syndrome-Treatment-Market

Global Dry Eye Syndrome MarketDry eye syndrome, medically known as keratoconjunctivitis sicca, is an ocular disorder caused by the lack of tear fluid to lubricate the eyes.

This can be an indicator of either low production of tears or rapid evaporation of the film of tears on the surface of the eyes, which can be brought about by several conditions.

Dry eye syndrome is one of the most common eye disorders around the world and is particularly common in the geriatric demographic.

All these treatments have different mechanisms: artificial tears can close up the deficiency of natural tears to lubricate the eyes, steroid drops help soothe inflammation around the eye to stimulate natural tear production, warm compressors help increase the activity of glands around the eyes required to produce tears, and punctal plugs help keep tears on the surface of the eyes for a longer period.Request COVID Analysis on Dry Eye Syndrome Treatment Market –  https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=10844 Global Dry Eye Syndrome Market: Drivers and RestraintsThe growth of the global dry eye syndrome market is primarily due to the increase in the overall prevalence of dry eye syndrome, which is attributable to a combination of several factors.The rising geriatric population around the world has led to an upsurge in the overall prevalence of dry eye syndrome, as tear glands weaken due to aging and can’t produce sufficient tear fluid to maintain a lubricating film over the eyes.The high prevalence of other conditions that can affect the functioning of the eye, such as diabetes, is another major factor boosting the prevalence of dry eye syndrome.

The changes in the composition of the patient’s blood due to diabetes can affect tear glands adversely, causing dry eye syndrome.

Other conditions that can indirectly cause dry eye syndrome include vitamin A deficiency, lupus, thyroid disorders, and rheumatoid arthritis.Request Customization on Dry Eye Syndrome Treatment Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR_id=10844 The global dry eye syndrome market has also been boosted by the increasing awareness among the population about this disease.

 Market Analysis and Insights: Europe Dry Eye Syndrome Treatment MarketEurope Dry Eye Syndrome Treatment Market By Product Type (Emulsions, Lubricant Eye Drops/Solutions, Eye Ointments, Autologous Serum Eye Drops, Nutrition Supplements, Others), Disease Type (Evaporative Dry Eye Syndrome, Aqueous Dry Eye Syndrome), Treatment Type (Lubricating Agents, Tear Stimulators, Artificial Tears, Anti-Inflammatory Drugs, Antibiotic Drugs, Others), End User (Home Healthcare, Hospitals, Clinics, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), Country (Germany, U.K, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Turkey, Rest of Europe)– Industry Trends & Forecast to 2026Dry eye syndrome is a condition which has an increasing prevalence along with the increasing ages.

It is around 50.0% more common in the women as compared to men.

Dry eye if left untreated can lead to ulcers, pain, scars on the cornea or some loss of the vision.

However, the permanent loss of vision due to dry eye is uncommon.Download Free PDF Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-dry-eye-syndrome-treatment-marketDry eye syndrome can be associated with:Any disease process which helps in altering the components of the tearsCosmetic surgery, if eye-lids are opened widelyInflammation of surface of the eyes, the conjunctiva or the lacrimal glandGrowth in the surface of the eyes, as in thyroid diseases when the eyes protrude forwardEurope dry eye syndrome treatment market is projected to register a substantial CAGR in the forecast period of 2019 to 2026.Segmentation: Europe Dry Eye Syndrome Treatment MarketEurope dry eye syndrome treatment market is segmented into five notable segments which are product type, disease type, treatment type, end user and distribution channel.On the basis of product type, the market is segmented into emulsions, lubricant eye drops/solutions, eye ointments, nutrition supplements, autologous serum eye drops and othersOn the basis of disease type, the market is segmented into evaporative dry eye syndrome and aqueous dry eye syndromeOn the basis of treatment type, the market is segmented into tear stimulators, lubricating agents, anti-inflammatory drugs, artificial tears, antibiotic drugs and othersOn the basis end user, the market is segmented into of home healthcare, hospitals, clinics and othersOn the basis of distribution channel, the market is segmented into of hospital pharmacies, retail pharmacies, online pharmacies and othersFor More Information or Query or Looking for Customization, Visit @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-dry-eye-syndrome-treatment-market Competitive Analysis: Europe Dry Eye Syndrome Treatment MarketSome of the major players operating in this market are Mitotech, SA, Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd., ALLERGAN, Novaliq GmbH, Prestige Consumer Healthcare, Inc., Horus Pharma, Senju Pharmaceutical Co. Ltd., VISUfarma, Akorn, Incorporated, Bausch & Lomb Incorporated, Teva Pharmaceutical Industries Ltd., Alcon Inc., Santen Pharmaceutical Co., Ltd., Novartis AG, Similasan and others.Recent DevelopmentsIn September 2019, VISUfarma team will be presented at the 37th Annual Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) which will be held from 14th to 18th September in Paris.

This strategy will help the company to give insights regarding their products and increase their customer base.In June 2019, VISUfarma team presented at the XV Annual National Congress of the Società Italiana Glaucoma (SIGLA) which was held from 13th to 15th June in Italy.

This strategy will help the company to give insights regarding their products and increase their customer base.In May 2019, VISUfarma team presented at the 32nd Annual Congress of the Deutschen Ophthalmochirurgen (DOC) which was held from 23rd to 25th May in Germany.